Summary.-Peripheral plasma levels of immunoreactive 6-oxo-PGF1a, the stable hydrolysis product of prostacyclin, were significantly higher in female patients with tumours of the genital tract than in normal controls. In the groups with malignant tumours, these high levels declined after operation and/or radiotherapy if the tumour responded to treatment. In patients who did not respond to treatment or with tumour recurrence, levels of plasma 6-oxo-PGF,a remained high or even rose further. Benign gynaecological tumours were also associated with significantly raised plasma 6-oxo-PGFjoc levels, and these fell to normal levels immediately on surgical removal of the tumour. Possible reasons for these alterations are described. Further investigations are warranted to see whether serial measurements of plasma 6-oxo-PGF,a. could be used as a prognostic index for the clinical status of patients with gynaecological tumours.
6-oxo-PGF,a. could be used as a prognostic index for the clinical status of patients with gynaecological tumours.
THE PRESENCE of prostaglandins in virtually all cell types so far studied and their potent biological activity has prompted their study in patients with malignant tumours. Increased synthesis of prostaglandins by tumour tissues of thyroid , phaeochromocytoma and bronchus (Sandler et al., 1968) , kidney (Cummings & Robertson, 1977) , breast (Bennett et al., 1975) and endometrium (Singh et al., 1976; Willman et al., 1976) have been described. Raised plasma levels of prostaglandins or their metabolites have been measured in the peripheral circulation and across the tumour bed in patients with both genitaltract and breast tumours (Sanders et al., 1980; Powles et al., 1977; Stamford et al., 1980 , derived from Mortel et al., 1977 . This has led to the suggestion that plasma prostaglandin measurements might be a potentially useful tumour marker.
Prostacyclin (PGI2), a very potent vasodilator and anti-platelet-aggregating agent, is the major product of the cyclooxygenase enzyme pathway in a variety of tissues (Moncada & Vane, 1979) . Unlike the primary prostaglandins, PGI2 is neither metabolized by the lung (Hawkins et al., 1978) nor is it formed in vitro during blood sampling and preparation. Prostacyclin is spontaneously hydrolysed to 6-oxo-PGF,a, a metabolite which has been used extensively as a measure of PGI2 production. Khan et al. (1980) have found significantly raised levels of plasma 6-oxo-PGF,a in patients with malignant prostatic disease. In this preliminary study we have measured plasma 6-oxo-PGF,cx in patients with a variety of gynaecological tumours, and examined serial changes after surgery and/or chemotherapy or radiotherapy and at shortterm follow-up.
PATIENTS AND METHODS
Twenty patients formed the control group.
Ten of these underwent major gynaecological surgery for conditions other than a tumour, and 10 were being treated medically for minor problems such as vaginitis.
Of the 52 patients with gynaecological tumours, 15 had benign tumours and 37 malignant tumours. Of the benign-tumour group 12 had uterine fibroids and 3 had an ovarian cyst. The malignant group consisted of carcinoma of the ovary (17), carcinoma of the cervix (16) and carcinoma of the uterus (4).
Venous blood (5 ml) was taken from the antecubital vein into EDTA and immediately centrifuged at 1500 g for 10 min at 4°C. -Plasma was separated and stored at -20°C. Levels of 6-oxo-PGFla were assayed by specific radioimmunoassay (Myatt et al., 1981) 
RESULTS
The plasma immunoreactive 6-oxo-PGF,cx levels in the various study groups are shown in Tables I & II .
Control group
Plasma 6-oxo-PGFloz levels of 93 + 32 pg/ml (mean + s.d.) in the control group were similar to those previously measured in normal subjects (Myatt et al., 1981) ; the mean postoperative value of 103 + 30 pg/ml found in the 10 patients who underwent major gynaecological surgery for a non-malignant condition was not significantly different from that of the control values.
Benign tumour group
The pre-operative plasma 6-oxo-PGF1o, levels were significantly higher (P < 0.05) in this group than in the control group. After removal of the tumour, high 6-oxo-PGF,ox levels fell to the normal range in all the patients ( (n=15) 57-5 (40) 267+55** ** 199+38** ** 141+72 (n= 10) (b) Non-responders (n= 6) 71-5 (15) 202 + 103** 175+123 225+66*** Postoperative samples were taken at 7-8 days after operation and follow-up samples at 6-7 weeks. Significance of differences * P<0 05, ** P<0-01, *** P<0-001, as in Table I. plasma 6-oxo-PGF,a levels were sigiificantly raised (P<0001) at the time of diagnosis (Table I) . After a total hysterectomy and during subsequent follow-up, plasma 6-oxo-PGF1a levels were comparable to those of controls. The 5 patients with Stage I-IV disease had raised levels of plasma 6-oxo-PGF1oz but unrelated to Stage. weeks, and to the normal range by 3 months (80 + 28 pg/ml: Table I ). Carcinoma of the ovary and uterus.-There were 17 patients with carcinoma of the ovary in this group, with disease ranging from Stage Ia to IV (FIGO), and 4 with carcinoma of the uterus.
The changes in plasma 6-oxo-PGF,cx levels in both groups of patients were dependent on the clinical outcome. In view of the few carcinomas of the uterus, both groups were combined for analysis.
Pre-operative plasma 6-oxo-PGF,a levels were significantly high, both those responsive and those irresponsive to therapy (Table II) but with no significant difference between these two groups.
Responders
In 12 patients with carcinoma of the ovary the operation was total abdominal hysterectomy, bilateral salpingo-oophorectomy, removal of tumour and omentectomy, followed by chemotherapy. All 12 responded to treatment and are alive, and their 6-oxo-PGF,ox levels had fallen considerably after surgery and at followup (Fig. 2) . Of the 7 cases available for follow-up, 3 were studied more closely.
In these patients plasma 6-oxo-PGF,a levels fell postoperatively (Fig. 2) but a subsequent rise was seen while they were awaiting chemotherapy. Once chemotherapy was started, plasma 6-oxo-PGF,a levels fell, with concurrent clinical improvement in all patients.
Three of the 4 patients with carcinoma of the uterus were operable, responded to radiotherapy, and are alive and well. Both postoperatively and after radio-L) .
PLASMA 6-OXO-PGFix0 AND GYNAECOLOGICAL TUMOURS therapy, plasma 6-oxo-PGFloc levels fell to normal. In the combined group of responsive patients, significant reductions 4501 of plasma 6-oxo-PGFjoc occurred in the postoperative and follow-up periods (Table  II) . Although the levels were still significantly higher than normal postoperatively, they had fallen to within the normal range at follow-up. Follow-up patients Non-responders Five patients with carcinoma of the ovary and one with carcinoma of the uterus were found to be inoperable. None of these responded to chemotherapy and all subsequently died. The mean plasma 6-oxo-PGF1oc levels were significantly raised before laparotomy (Table  II) , were not significantly affected by chemotherapy, and were still significantly above normal at follow-up. This contrasted with the group of patients who responded to therapy, in all of whom plasma 6-oxoPGF10a fell.
DISCUSSION
Plasma 6-oxo-PGF1oz levels in the control group of patients were not altered by major surgery. To our knowledge no other study has shown an increase in prostaglandin production associated with a benign tumour. The apparent relationship between benign tumour size (fibroid or ovarian cyst) and plasma 6-oxo-PGF1o, suggested either that the tumour produced and released PG12 into the peripheral circulation or that increased PGI2 production may be associated with the increased vascular supply to these tumours. Plasma 6-oxo-PGFlox levels rise during normal pregnancy, perhaps in association with the increased uterine vascularity (Bolton et al., in press) .
Primary prostaglandin concentrations are increased in plasma (Sanders et al., 1980) , tumour tissues (Singh et al., 1976; Willman et al., 1976) and across the tumour bed (Stamford et al., 1980 , derived from Mortel et al., 1977 in patients with gynaecological tumours. The lack of PG12 metabolism by the lung (Hawkins et al., 1978) , and its spontaneous hydrolysis in plasma to 6-oxo-PGF1x, which has a relatively u I long half-life, both facilitates measurement and makes plasma measurements more meaningful than for the primary prostaglandins.
In contrast to Sanders et al. (1980) , who measured peripheral plasma PGF, we found no correlation between either tumour type or stage of differentiation and plasma 6-oxo-PGF,ac levels. However, other reports show a conflict over the correlation between tumour differentiation and PG production (Khan et al., in press; Bennett et al., uinpublished: Rolland et al., 1980) . Plasma 6-oxo-PGF,o levels fell in cases of carcinoma of the ovary or uterus after surgery, or if the tumour subsequently responded to chemotherapy or radiotherapy, but rose in all patients whose tumours did not respond to therapy. The clinical progression of such tumours may perhaps be monitored, though the origin of the increased 6-oxo-PGF,ox is uncertain. Our observations on the carcinoma of the ovary group suggest that chemotherapy should be started as soon as possible. The differences between chemotherapy-responsive and non-responsive patients with carcinoma of the ovary suggest that a reduction of plasma 6-oxoPGFjjx is secondary to tumour regression rather than a direct effect of chemotherapy on the prostaglandin synthetic pathways.
The findings of significantly raised plasma 6-oxo-PGFlcx levels in patients pre-treatment plasma 6-oxo-PGF,oa levels. The slower fall in 6-oxo-PGF1I in these patients after radiotherapy may indicate a slower rate of tumour regression. However, the inflammatory response of irradiated tissues may stimulate PGJ2 production (Tanner et al., 1981) which masks the fall in production by tumour tissue. Therefore in these patients plasma 6-oxo-PGF,oa may not be initially such an accurate marker for the clinical response of the tumour itself, though it undoubtedly is at follow-up. Our findings add to the weight of evidence for increased plasma prostaglandin levels in cancer patients. Serial measurements of 6-oxo-PGF,x may, with some reservations such as treatment with radiotherapy, provide a useful guide to the clinical progression of the disease, though they have to be used with caution to diagnose malignancy. In vitro experiments, more invasive sampling techniques and a larger study are needed to clarify the source of prostaglandin, or its possible correlation with disease stage. The potent vasodilator and platelet-anti-aggregation properties of prostacyclin bring into question its role in dissemination of cancer.
